Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats
Autore:
Ueno, M; Miyauchi, T; Sakai, S; Goto, K; Yamaguchi, I;
Indirizzi:
Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Cardiovasc, Tsukuba, Ibaraki 3058575, Japan Univ Tsukuba Tsukuba Ibaraki Japan 3058575 sukuba, Ibaraki 3058575, Japan Univ Tsukuba, Inst Basic Med Sci, Dept Pharmacol, Tsukuba, Ibaraki 3058575, Japan Univ Tsukuba Tsukuba Ibaraki Japan 3058575 sukuba, Ibaraki 3058575, Japan Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan Univ Tsukuba Tsukuba Ibaraki Japan 3058575 sukuba, Ibaraki 3058575, Japan
Titolo Testata:
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
, volume: 36, anno: 2000, supplemento:, 1
pagine: S305 - S310
SICI:
0160-2446(2000)36:<S305:EAAOPA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
VASOCONSTRICTOR PEPTIDE; HEART-FAILURE; EPOPROSTENOL PROSTACYCLIN; ENDOGENOUS ENDOTHELIN-1; CARDIAC-FUNCTION; SURVIVAL; VASODILATION; THROMBOSIS; MECHANISM; INCREASE;
Keywords:
pulmonary hypertension (PH); endothelin-A-(ETA) receptor antagonist; prostacyclin analog; right ventricular hypertrophy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Miyauchi, T Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Cardiovasc, Tsukuba, Ibaraki 3058575, Japan Univ Tsukuba Tsukuba Ibaraki Japan 3058575 aki 3058575, Japan
Citazione:
M. Ueno et al., "Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats", J CARDIO PH, 36, 2000, pp. S305-S310

Abstract

Pulmonary hypertension (PH) has a Door prognosis and is a drug-resistant disease. Recently. it has been reported that continuous intravenous prostacyclin (PGI(2)) administration is effective for PH. In this study, we compared the effects of chronic treatment with an endothelin-A- (ETA) receptor antagonist with an oral PGI(2) analog on PH in rats. We administered the ETA-receptor antagonist TA-0201 or beraprost sodium (BPS), which is an orally active PGI(2) analog, to monocrotaline- (MCT) induced PII rats. Each drug wasgiven orally for 19 days. The rats were divided into the following four groups: (1) normal rats with vehicle (control); (2) PH rats with vehicle treatment (PH + vehicle); (3) PH rats with TA-0201 treatment (0.5 mg/kg/day) (PN + TA-0201); (4) PH rats with BPS treatment (100 mug/kg/day) (PH + BPS). Nineteen days after MCT injection, Pp/Ps (the ratio of right ventricular (RV) systolic pressure to systemic systolic blood pressure) and the ratio of the RV weight to the body weight (RV/BW), indicators of PH and RV hypertrophy, were markedly higher in the PH + vehicle group than in the control (healthy) group. The increase in Pp/Ps and RV/BW was significantly depressed in the PH + TA-0201 group and PH + BPS group to a similar extent. The expression of P-myosin heavy chain (MHC) mRNA, a molecular marker for cardiac hypertrophy, in the RV was greatly increased in the PH + vehicle group and this increase was inhibited in the PH + TA-0201 group and PH + BPS group to a similar effect. In conclusion, treatment with an ETA-receptor antagonist or an oral PGI(2) analog is comparably effective in the prevention of progression of PH and RV hypertrophy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 22:17:24